B2BinPay v20 Increases Functionality with TRX Staking and Broader Blockchain Support
6.6.2024 11:31:00 EEST | Business Wire | Press release
The industry-leading blockchain platform, B2BinPay, has improved even further. The most recent version offers clients more flexibility and efficiency by expanding blockchain functionality and introducing TRX staking. Let's review how these new features improve B2BinPay's user experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606092849/en/
B2BinPay version 20 arrives with TRX staking feature and expanded blockchain support (Graphic: Business Wire)
TRX Staking – Earn While You Transact!
The launch of TRX Staking, based on the advanced Stake 2.0 mechanism developed by the TRON community, is a crucial highlight of B2BinPay v20. With its increased flexibility, simplified user interface, and improved resource delegation and utilisation efficiency, this new approach surpasses the previous Stake 1.0.
TRX staking empowers B2BinPay clients to stake any amount of TRX and earn a passive annual yield of 3-5% (subject to network conditions). But this is not all. By staking TRX, users can significantly reduce transaction fees on the TRON network. Staked TRX is converted into bandwidth and energy, two necessary resources, to achieve this.
Smart contracts run on energy, and transaction processing capability is provided by bandwidth. By staking TRX and acquiring these resources, companies and individuals can increase transaction efficiency and save operating costs, providing them a distinct competitive advantage.
Getting started with TRX Staking on B2BinPay is straightforward:
➔ Begin by converting your TRX into either Bandwidth or Energy based on the specific processing needs of your chosen asset type.
➔ After that, delegate your votes converted from Bandwidth or Energy to SR.
New Blockchains Supported
Building on the previous integration of Polygon and Avalanche, the addition of Optimism, Arbitrum, and Base—all of which provide native support for stablecoins—significantly broadens B2BinPay v20's support for blockchain technology.
Optimism
Optimism is a Layer 2 solution that scales the Ethereum leading network by batching transactions. It collects transaction data from the Ethereum blockchain, processes it in batches, and sends it back to the Ethereum mainnet for validation. Since its launch in 2021, Optimism has reduced fees by ten times compared to Ethereum's base level. Users have saved over $1 billion in gas payments, making it one of the most cost-effective blockchains.
Arbitrum
Arbitrum is an Ethereum scaling solution that increases transaction volumes while lowering costs. It shares Ethereum's tooling, enabling developers to deploy DApps on Arbitrum quickly and securely. This compatibility extends to stablecoins, offering users more choices.
Base
Base, developed by Coinbase, optimises Optimism’s OP Stack for enhanced EVM compatibility. This open-source rollup supports stablecoins and makes code deployment easier on Ethereum and compatible blockchains.
Why Does Expanded Blockchain Support Matter for Clients?
By incorporating additional blockchains, B2BinPay expands the range of transaction options, aligning with your business requirements using suitable technology. Specifically, B2BinPay now supports:
USDT on 7 networks:Ethereum, Binance Smart Chain, Tron, Avalanche, Polygon, Optimism, and Arbitrum.
USDC on 8 networks: Ethereum, Binance Smart Chain, Tron, Avalanche, Polygon, Optimism, Arbitrum, and Base.
Bridged USDC on 4 networks: Avalanche, Polygon, Optimism, and Arbitrum.
Here are other use cases of how the blockchain expansion can benefit you.
Streamlining Withdrawals for End-Users
Suppose your end-user needs to withdraw funds in a currency that's not immediately available. In that case, B2BinPay allows for swift asset conversion to meet currency requirements and handle associated transaction fees, ensuring the timely fulfilment of withdrawal requests.
Reducing Blockchain Transaction Fees
If you aim to lower the cost of USDT transactions, B2BinPay offers an effective solution by allowing you to aggregate USDT from various blockchains, such as Ethereum or Optimism, into a single swap wallet.
Ensuring Liquidity for Trading Platforms
Suppose you have significant cryptocurrency funds and urgent requirements like stopouts on trading platforms. In that case, you can rely on B2BinPay's extensive blockchain support to quickly convert assets into the required currency for deposit. This feature assists you in maintaining liquidity and enables quick responsiveness to market demands.
Final Remarks
According to the official statements, Algorand and Solana will be introduced in the upcoming release. With this expansion, there will be 10 blockchains that enable stablecoin transactions, including those already used: Ethereum, Tron, Binance Smart Chain, Avalanche, Polygon, Optimism, Arbitrum, and Base.
Connect with B2BinPay and unlock your business potential with advanced blockchain payment processing solutions!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606092849/en/
Contact information
sales@b2binpay.com
+357 250-308-82
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom